Although its treatment for Crohn's disease missed the primary endpoint in a Phase II trial, Millennium Pharmaceuticals Inc. said the drug hit a secondary endpoint and the company is awaiting results from another Phase II study, this one for ulcerative colitis, with the monoclonal antibody MLN02. (BioWorld Today) Read More
